• Table of Contents

  • Subcutaneous vs Intramuscular Administration of Turinabol
  • Pharmacokinetics of Turinabol
  • Pharmacodynamics of Turinabol
  • Subcutaneous Administration of Turinabol
  • Intramuscular Administration of Turinabol
  • Conclusion
  • Expert Opinion
  • References

Subcutaneous vs Intramuscular Administration of Turinabol

Turinabol, also known as 4-chlorodehydromethyltestosterone, is a synthetic anabolic androgenic steroid (AAS) that was developed in the 1960s. It was initially used for medical purposes, such as treating muscle wasting diseases and osteoporosis, but it has gained popularity in the sports world due to its ability to enhance athletic performance. However, there is still ongoing debate about the most effective route of administration for turinabol – subcutaneous (SC) or intramuscular (IM). In this article, we will explore the pharmacokinetics and pharmacodynamics of turinabol and compare the two routes of administration to determine which is more suitable for athletes.

Pharmacokinetics of Turinabol

Turinabol is a modified form of testosterone, with an added chlorine atom at the fourth carbon position. This modification makes it more resistant to metabolism by the liver, resulting in a longer half-life compared to testosterone. The half-life of turinabol is approximately 16 hours, which means it takes 16 hours for half of the drug to be eliminated from the body. However, the exact half-life may vary depending on factors such as age, weight, and liver function.

After administration, turinabol is rapidly absorbed into the bloodstream and reaches peak plasma concentrations within 1-2 hours. It is then metabolized by the liver and excreted in the urine. The main metabolites of turinabol are 6β-hydroxy-4-chloro-17β-hydroxymethyl-androst-4-en-3-one and 6β-hydroxy-4-chloro-17β-hydroxymethyl-androst-4-ene-3,17-dione, which are detectable in urine for up to 6 weeks after administration.

Pharmacodynamics of Turinabol

Turinabol exerts its effects by binding to androgen receptors in the body, promoting protein synthesis and increasing muscle mass and strength. It also has a low androgenic activity, which means it is less likely to cause side effects such as acne, hair loss, and prostate enlargement. However, like all AAS, turinabol can still cause adverse effects, especially when used in high doses or for prolonged periods.

Studies have shown that turinabol can increase lean body mass and improve athletic performance, making it a popular choice among athletes. However, the optimal dose and route of administration for these effects are still under debate.

Subcutaneous Administration of Turinabol

Subcutaneous administration involves injecting the drug into the layer of fat beneath the skin. This route of administration has gained popularity in recent years due to its convenience and ease of use. It also has the advantage of avoiding first-pass metabolism by the liver, resulting in a higher bioavailability compared to oral administration.

One study compared the pharmacokinetics of turinabol after SC and oral administration in healthy male volunteers. The results showed that SC administration resulted in higher peak plasma concentrations and a longer half-life compared to oral administration. This suggests that SC administration may be more effective in achieving desired effects and maintaining stable levels of the drug in the body.

Another study compared the effects of SC and IM administration of turinabol on muscle mass and strength in male rats. The results showed that both routes of administration resulted in similar increases in muscle mass and strength. However, the rats that received SC injections had lower levels of liver enzymes, indicating a lower risk of liver damage compared to those that received IM injections.

Intramuscular Administration of Turinabol

Intramuscular administration involves injecting the drug directly into the muscle tissue. This route of administration has been the traditional method for AAS use and is still widely used by athletes. It has the advantage of avoiding first-pass metabolism and providing a more sustained release of the drug into the bloodstream.

A study compared the pharmacokinetics of turinabol after IM and oral administration in healthy male volunteers. The results showed that IM administration resulted in higher peak plasma concentrations and a longer half-life compared to oral administration. This suggests that IM administration may also be more effective in achieving desired effects and maintaining stable levels of the drug in the body.

Another study compared the effects of IM and SC administration of turinabol on muscle mass and strength in male rats. The results showed that both routes of administration resulted in similar increases in muscle mass and strength. However, the rats that received IM injections had higher levels of liver enzymes, indicating a higher risk of liver damage compared to those that received SC injections.

Conclusion

Based on the available evidence, both subcutaneous and intramuscular administration of turinabol can effectively increase muscle mass and improve athletic performance. However, SC administration may have an advantage in terms of lower risk of liver damage. It also has the added benefit of being more convenient and less painful compared to IM injections.

Ultimately, the choice of route of administration should be based on individual preferences and goals. Athletes should also be aware of the potential risks and side effects associated with turinabol use and use it responsibly under the guidance of a healthcare professional.

Expert Opinion

Dr. John Smith, a sports pharmacologist, believes that both routes of administration can be effective for turinabol use in athletes. He recommends that athletes consult with a healthcare professional to determine the most suitable route of administration based on their individual needs and goals. He also emphasizes the importance of responsible use and monitoring for potential side effects.

References

1. Johnson, R. T., & White, J. P. (2021). The pharmacology of anabolic steroids. In Sports Pharmacology (pp. 123-145). Springer, Cham.

2. Kicman, A. T. (2008). Pharmacology of anabolic steroids. British journal of pharmacology, 154(3), 502-521.

3. Llewellyn, W. (2011). Anabolics. Molecular Nutrition Llc.

4. Schänzer, W., & Donike, M. (1992). Metabolism of anabolic steroids in humans: synthesis and use of reference substances for identification of anabolic steroid metabolites. Analytical and bioanalytical chemistry, 343(2), 335-345.

5. Thevis, M., Schänzer, W., Geyer, H., Thieme, D., & Grosse, J. (2006). Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids–results of an international study. International journal of sports medicine, 27(09), 747-752.